Based on the immatics biotechnologies GmbH stock forecast from 0 analysts, the average analyst target price for immatics biotechnologies GmbH is not available over the next 12 months. immatics biotechnologies GmbH’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of immatics biotechnologies GmbH is Slightly Bullish , which is based on 6 positive signals and 3 negative signals. At the last closing, immatics biotechnologies GmbH’s stock price was EUR 6.50. immatics biotechnologies GmbH’s stock price has changed by -4.13% over the past week, -11.87% over the past month and -24.74% over the last year.
No recent analyst target price found for immatics biotechnologies GmbH
No recent average analyst rating found for immatics biotechnologies GmbH
Company Overview immatics biotechnologies GmbH
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany. Read Less
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid t...Read More
Frequently Asked Questions About immatics biotechnologies GmbH (4A3:F) Stock
Stock Target Advisor's fundamental analysis for immatics biotechnologies GmbH's stock is Slightly Bullish .
Unfortunately we do not have enough data on 4A3:F's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on 4A3:F's stock to indicate what its average analyst target is.
4A3:F stock's Price/Earning ratio is 15.48.
Our analysis grades 4A3:F stock's Price / Earning ratio at F. This means that 4A3:F stock's Price/Earning ratio is above 42.00000000000001% of the stocks in the Biotechnology sector in the F exchange.
Based on this 4A3:F may be fairly valued for its sector
The last closing price of 4A3:F's stock was EUR 6.50.
The most recent market capitalization for 4A3:F is EUR 0.89B.
Unfortunately we do not have enough analyst data on 4A3:F's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains immatics biotechnologies GmbH's stock.
As per our most recent records immatics biotechnologies GmbH has 542 Employees.
immatics biotechnologies GmbH's registered address is Paul-Ehrlich-Strasse 15, Tübingen, Germany, 72076.
You can get more information about it from immatics biotechnologies GmbH's website at https://www.immatics.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About immatics biotechnologies GmbH (4A3:F) Stock
Stock Target Advisor's fundamental analysis for immatics biotechnologies GmbH's stock is Slightly Bullish .
Unfortunately we do not have enough data on 4A3:F's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on 4A3:F's stock to indicate what its average analyst target is.
4A3:F stock's Price/Earning ratio is 15.48.
Our analysis grades 4A3:F stock's Price / Earning ratio at F. This means that 4A3:F stock's Price/Earning ratio is above 42.00000000000001% of the stocks in the Biotechnology sector in the F exchange.
Based on this 4A3:F may be fairly valued for its sector
The last closing price of 4A3:F's stock was EUR 6.50.
The most recent market capitalization for 4A3:F is EUR 0.89B.
Unfortunately we do not have enough analyst data on 4A3:F's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains immatics biotechnologies GmbH's stock.
As per our most recent records immatics biotechnologies GmbH has 542 Employees.
immatics biotechnologies GmbH's registered address is Paul-Ehrlich-Strasse 15, Tübingen, Germany, 72076.
You can get more information about it from immatics biotechnologies GmbH's website at https://www.immatics.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for 4A3:F !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
